Standard Biotools Inc (LAB) - Total Liabilities
Based on the latest financial reports, Standard Biotools Inc (LAB) has total liabilities worth $87.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Standard Biotools Inc to see how much of total assets are deployed in long-term investments.
Standard Biotools Inc - Total Liabilities Trend (2006–2025)
This chart illustrates how Standard Biotools Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LAB current and non-current assets.
Standard Biotools Inc Competitors by Total Liabilities
The table below lists competitors of Standard Biotools Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ingevec
SN:INGEVEC
|
Chile | CL$216.22 Billion |
|
LNA Sante SA
PA:LNA
|
France | €1.25 Billion |
|
Lightron Inc.
KQ:069540
|
Korea | ₩28.14 Billion |
|
Bait Bakfar Ltd
TA:BKFR
|
Israel | ILA1.01 Billion |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
USA | $2.48 Billion |
|
Compucase Enterprise Co Ltd
TW:3032
|
Taiwan | NT$14.44 Billion |
|
Dharma Polimetal Tbk PT
JK:DRMA
|
Indonesia | Rp1.55 Trillion |
|
Keyfield International Berhad
KLSE:5321
|
Malaysia | RM395.05 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Standard Biotools Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Standard Biotools Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Standard Biotools Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Standard Biotools Inc (2006–2025)
The table below shows the annual total liabilities of Standard Biotools Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $143.46 Million | +2.02% |
| 2024-12-31 | $140.62 Million | -70.15% |
| 2023-12-31 | $471.12 Million | -0.14% |
| 2022-12-31 | $471.78 Million | +161.20% |
| 2021-12-31 | $180.62 Million | -2.74% |
| 2020-12-31 | $185.71 Million | +67.00% |
| 2019-12-31 | $111.20 Million | -51.97% |
| 2018-12-31 | $231.53 Million | -9.70% |
| 2017-12-31 | $256.42 Million | +1.29% |
| 2016-12-31 | $253.16 Million | -1.17% |
| 2015-12-31 | $256.16 Million | -0.38% |
| 2014-12-31 | $257.14 Million | +1198.88% |
| 2013-12-31 | $19.80 Million | +51.41% |
| 2012-12-31 | $13.07 Million | -41.70% |
| 2011-12-31 | $22.43 Million | -89.52% |
| 2010-12-31 | $213.97 Million | +3.98% |
| 2009-12-31 | $205.77 Million | +7.91% |
| 2008-12-31 | $190.69 Million | +3.02% |
| 2007-12-31 | $185.11 Million | +29.75% |
| 2006-12-31 | $142.66 Million | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more